Tag archive for immunotherapies

- Jul 10 2017
- PDS-Biotech
PDS Biotechnology Corp. Announces Clinical Collaboration with Merck to Evaluate Combination of Versamune® PDS0101 and KEYTRUDA® (pembrolizumab) for Metastatic Head and Neck Cancer
- Standard
- clinical trial, immuno-oncology, immunotherapies, Keytruda, Merck, PDS Biotechnology, PDS0101, versamune
North Brunswick, NJ, July 10, 2017 /PRNewswire/ — PDS Biotechnology Corporation (“PDS”), a private clinical stage immuno-oncology company developing novel immunotherapies, has entered a clinical trial collaboration agreement with a subsidiary of Merck (known as MSD outside the United States and […]
Read more
- Jun 07 2016
- PDS-Biotech
PDS Biotechnology Release: CEO Frank Bedu-Addo Presenting at BIO 2016
- Standard
- CD8 + T-cell induction results, clinical stage, Frank Bedu-Addo, immuno-oncology, immunotherapies, PDS Biotechnology
North Brunswick, NJ: PDS Biotechnology, a private clinical stage immuno-oncology company developing novel immunotherapies, announces that CEO Frank Bedu-Addo will make a presentation at BIO 2016, being held at the Moscone Center, 747 Howard Street, San Francisco, California from June […]
Read more

©2017 PDS Biotechnology Corporation. All rights reserved.

Scroll